PharmaCielo Q2 2023 Results: Revenue Drops But CEO Is Optimistic About Future Growth
PharmaCielo Q2 2023 Results: Revenue Drops But CEO Is Optimistic About Future Growth
PharmaCielo Ltd. (TSXV:PCLO) (OTCQX:PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced its financial results on Tuesday for the second quarter ended June 30, 2023.
PharmaCielo Ltd.加拿大PharmaCielo哥倫比亞控股有限公司(TSXV：PCLO)(多倫多證券交易所股票代碼：PCLOF)週二公佈了截至2023年6月30日的第二季度財務業績。
"Our sales and finance teams have made measurable progress and I expect these efforts to continue to pay off over the next several quarters," stated Marc Lustig, chairman and CEO of PharmaCielo. "(...) Our finance team has delivered on our targeted 25% reduction in ongoing overhead expenses ahead of budget and with no meaningful impact on our ability to execute on existing contracts and go out and win new ones."
我們的銷售和財務團隊已經取得了可衡量的進展，我預計這些努力將在接下來的幾個季度繼續得到回報。梅克·盧斯蒂希，PharmaCielo董事長兼首席執行官。(……)我們的財務團隊已經實現了比預算提前25%的持續管理費用的目標，而且對我們執行現有合同和贏得新合同的能力沒有任何重大影響。“
Related Content: PharmaCielo Layoffs And Voluntary Salary Reductions To Decrease Its Annualized Fixed Costs By ~25%
相關內容：PharmaCielo裁員和自願減薪，將年化固定成本降低約25%
Q2 2023 Financial Highlights
2023年第二季度財務亮點
- Revenue: $160,000 CAD ($117.989), down from $2.1 million CAD ($1.5M) in Q2 2022.
- Adjusted EBITDA: Loss of $2.1 million ($1.5M), deeper than the $1.8 million CAD ($1.3M) loss in Q2 2022.
- Net Loss: $3.58 million CAD ($2.5M), a slight increase from the $3.51 million CAD ($2.58M) loss in Q2 2022.
- 收入：160,000加元(117.989美元)，低於2022年第二季度的210萬加元(150萬美元)。
- 調整後的EBITDA：虧損210萬加元(150萬美元)，比2022年第二季度180萬加元(130萬美元)的虧損更深。
- 淨虧損：358萬加元(250萬美元)，較2022年第二季度351萬加元(258萬美元)的虧損略有增加。
All figures are in Canadian dollars - CAD ($) unless otherwise specified.
除非另有說明，所有數位均以加元-加元($)表示。
"I strongly believe that the initiatives we have underway will result in meaningful growth in the top line, and with all material capex behind us, will translate into cash flow and growth in shareholder value," said Lustig.
Lustig說：“我堅信，我們正在實施的舉措將帶來有意義的營收增長，在我們身後有所有的物質資本支出後，將轉化為現金流和股東價值的增長。”
PharmaCielo Recent Developments
PharmaCielo的最新發展
- On July 11, 2023, PharmaCielo appointed Marc Lustig as Chairman and CEO.
- As of August 10, 2023, the company has seen steady sales progress, expecting its first shipment to a third Brazilian customer in Q4, continued shipments to a German customer, achieved a 25% reduction in overhead expenses year-over-year by Q2 2023, and reduced staff to 132 without compromising contract fulfillments.
- 2023年7月11日，PharmaCielo任命Marc Lustig為董事長兼首席執行官。
- 截至2023年8月10日，該公司的銷售取得了穩步進展，預計在第四季度向第三個巴西客戶發貨，繼續向德國客戶發貨，到2023年第二季度實現間接費用同比減少25%，並在不影響合同履行的情況下將員工人數減少到132人。
Related Content: Top Talent To Lead Two New US Marijuana Markets And Latest Key Hires In Cannabis Industry
相關內容：頂尖人才將領導美國兩個新的大麻市場和大麻行業的最新關鍵員工
Interested in learning about how to invest in cannabis stocks, consider joining us at the 17th edition of the Benzinga Cannabis Capital Conference, which is returning to Chicago on Sept 27-28.
有興趣學習如何投資大麻庫存，考慮加入我們的第17版本辛加大麻首都會議，它將返回到9月27日至28日芝加哥。
Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
在價格上漲之前今天就買到票，並在大麻投資和品牌推廣的中心獲得一席之地。
Price Action
價格行動
PharmaCielo's shares traded 0.46% lower at $0.1195 per share at the time of writing on Tuesday afternoon.
撰寫本文時，PharmaCielo的股價週二下午下跌0.46%，至每股0.1195美元。
Image by El Planteo
圖片由El Planteo提供